KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Change in Receivables (2016 - 2025)

Sarepta Therapeutics (SRPT) has 14 years of Change in Receivables data on record, last reported at $2.5 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 98.51% year-over-year to $2.5 million; the TTM value through Dec 2025 reached -$203.8 million, down 201.04%, while the annual FY2025 figure was -$203.8 million, 201.04% down from the prior year.
  • Change in Receivables reached $2.5 million in Q4 2025 per SRPT's latest filing, up from -$131.6 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $167.5 million in Q4 2024 and bottomed at -$132.1 million in Q2 2025.
  • Average Change in Receivables over 5 years is $14.8 million, with a median of $13.0 million recorded in 2022.
  • Peak YoY movement for Change in Receivables: skyrocketed 3598.81% in 2023, then tumbled 602.2% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $3.2 million in 2021, then surged by 309.58% to $13.1 million in 2022, then surged by 521.02% to $81.5 million in 2023, then skyrocketed by 105.55% to $167.5 million in 2024, then plummeted by 98.51% to $2.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $2.5 million in Q4 2025, -$131.6 million in Q3 2025, and -$132.1 million in Q2 2025.